Twice-Daily Oral Zinc in the Treatment of Patients With Coronavirus Disease 2019: A Randomized Double-Blind Controlled Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Zinc supplementation has been considered a potential therapy for coronavirus disease 2019 (COVID-19).

Who Took Part

PubMed indexes the participants as adults.

Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID-19-related hospitalization for outpatients.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

More than one site took part, so the participants came from several places.

The researchers conducted a prospective, randomized, double-blind, placebo-controlled multicenter trial.

What Was Measured

PubMed files the paper under topics including COVID-19, SARS-CoV-2 and Zinc.

The authors tagged it with the keywords outcome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Clinical infectious diseases : an official publication of the Infectious Diseases Society of America), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.